Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Here's how tesamorelin vs sermorelin and other GHRH peptides compare: GHRH Peptide Comparison Table Property Tesamorelin Sermorelin CJC-1295 (No DAC) CJC-1295 DAC FDA Status FDA Approved (Egrifta) Previously approved, now discontinued Not approved Not approved Amino Acids 44 (modified GHRH) 29 (GHRH 1-29) 29 + modifications 29 + Drug Affinity Complex Half-Life ~26-38 minutes ~10-20 minutes ~30 minutes ~6-8 days Mechanism GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist (extended) Clinical Trial Data Extensive (Phase 3 completed) Limited (older studies) Limited (Phase 1/2) Limited Primary Research Use Lipodystrophy, NAFLD, body composition GH deficiency research GH axis research Extended GH release research Key Differentiators Tesamorelin's advantages: Only GHRH analog with current FDA approval Extensive Phase 3 clinical trial data Documented efficacy for visceral fat reduction Well-characterized safety profile from prescription use Sermorelin note: Previously FDA-approved (1997) for pediatric growth hormone deficiency but discontinued by manufacturers no longer available as a prescription product in the US
A clinical study demonstrated that GPNA suppressed the expression of ASCT2 and diminished the uptake of Gln by cancer cells [169]
Figures 1BD show in vivo results of intraperitoneal administration of mAChR agonist and antagonist in metformin-treated and untreated animals
Non-hormonal therapies are also available for those who aren't candidates for or interested in HRT
Unfortunately taking oral glutathione directly does not work
We offer a range of IV infusions
US$ 24.80
US$ 25.62
US$ 23.79
